Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection

Chronic HBV Infection Clinical Trial

Official title:

A Phase 3, Randomized, Multicenter, Double-blind, Double-dummy, Parallel-controlled Study to Evaluate the Safety and Efficacy of HS-10234 25 mg QD Versus TDF 300 mg QD for the Treatment of Patients With HBeAg+/- Chronic HBV Infection.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03903796
• Other study ID #: HS-10234-301
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: August 16, 2018
• Est. completion date: September 30, 2023

Study information

• Verified date: February 2023
• Source: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to compare the safety and efficacy of HS-10234 versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with chronic hepatitis B virus (HBV) infection.

Description:

This is a phase 3, randomized, multicenter, double-blind, double-dummy, parallel-controlled, non-inferiority trial to evaluate the safety and efficacy of HS-10234 25 mg qd versus TDF 300 mg qd. Patients with chronic HBV infection who are positive or negative for the hepatitis B e antigen (HBeAg) will be randomly assigned (2:1) to receive either 25 mg HS-10234 or 300 mg TDF with matching placebo. Randomization will be done by a computer-generated allocation sequence stratified by plasma HBV DNA concentration (HBV DNA< 8 log10IU/mL；HBV DNA ≥8 log10IU/mL) and previous treatment experience (treatment-naive and treatment-experienced). All patients will receive 144 weeks of antiviral therapy. After 96 weeks of double-blind treatment, all subjects will be eligible to receive open-label HS-10234 until 144 weeks.

The primary efficacy endpoint is the proportion of patients with HBV DNA less than 20 IU/mL at week 48 in all patients who are randomly assigned and received at least one dose of study drug using a missing-equals-failed approach. Key pre-specified safety endpoints are bone and renal parameters at week 48. Other pre-specified endpoints include viral suppression, serologic response, normalization of alanine aminotransferase (ALT) levels and the emergence of resistance mutations at week 48, 96 and 144.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 963
• Est. completion date: September 30, 2023
• Est. primary completion date: May 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:

1. Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study screening.

2. Male and non-pregnant, non-lactating females, from 18 up to 65 years of age (based on the date of the screening visit). A negative serum pregnancy test at screening is required for female subjects of childbearing potential.

3. Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6 months).

4. HBeAg-positive or HBeAg-negative chronic hepatitis B with all of the following:

HBV DNA = 2 x 104 IU/mL; Screening serum 1 ULN < ALT level = 10 ULN.

5. Treatment-naive subjects (defined as < 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue) OR treatment-experienced subjects (defined as subjects meeting all entry criteria [including HBV DNA and serum ALT criteria] and with = 12 weeks of previous treatment with any nucleoside or nucleotide analogue) will be eligible for enrollment. Treatment-experienced subjects receiving oral antiviral treatment at Screening must continue their treatment regimen until the time of randomization, when it will be discontinued.

6. Any previous treatment with interferon (pegylated or non-pegylated) must have ended at least 6 months prior to the baseline visit.

7. Estimated creatinine clearance (CLcr) = 50 mL/min(using the Cockcroft-Gault method)based on serum creatinine and actual body weight as measured at the screening evaluation, as follows:

(140-age in years)(body weight [kg]) (72)(serum creatinine [mg/dL]) 8) Normal ECG (or if abnormal, determined by the Investigator not to be clinically significant).

9) Must be willing and able to comply with all study requirements.

Exclusion Criteria:

• Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:

1. Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study.

2. Males and females of reproductive potential who are unwilling to use an "effective", protocol specified method(s) of contraception during the study.

3. Co-infection with HCV virus, HIV, or HDV.

4. Evidence of hepatocellular carcinoma (e.g. as evidenced by recent imaging).

5. Any history of, or current evidence of, clinical hepatic decompensation (e.g. ascites encephalopathy or variceal hemorrhage).

6. Abnormal hematological and biochemical parameters, including:

• Hemoglobin < 10 g/dl

• Absolute neutrophil count < 0.75 × 109/L

• Platelets = 50 × 109/L

• AST or ALT > 10 × ULN

• Total Bilirubin > 2.5 × ULN

• Albumin < 3.0 g/dL

• INR > 1.5 × ULN (unless stable on anticoagulant regimen)

7. Received solid organ or bone marrow transplant.

8. Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of the investigator.

9. Significant bone disease (e.g. osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochrondroses), or multiple bone fractures.

10. Malignancy within the 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc).

11. Currently receiving therapy with immunomodulators (e.g. corticosteroids), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion.

12. Known hypersensitivity to study drugs, metabolites, or formulation excipients.

13. Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance.

14. Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.

15. Subjects on prohibited concomitant medications. Subjects on prohibited medications, otherwise eligible, will need a wash out period of at least 30 days.

Related Conditions & MeSH terms

• Chronic HBV Infection
• Communicable Diseases
• Infections

Intervention

Drug:
• HS-10234
Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
• TDF
Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily

Locations

Country	Name	City	State
China	The First Hospital of Jilin University	Changchun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Evaluation the proportion of Patients Achieving Hepatitis B Surface Antigen (HBsAg) Loss	Proportion of Patients Achieving Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 96, 144	Week 48, 96 and 144
Other	Evaluation the proportion of Patients Achieving HBsAg Seroconversion	Proportion of Patients Achieving HBsAg Seroconversion at Weeks 48, 96, 144	Week 48, 96 and 144
Other	Evaluation the proportion of patients achieving HBeAg loss	Proportion of patients achieving HBeAg loss at weeks 48, 96, 144	Week 48, 96 and 144
Other	Evaluation the proportion of patients achieving HBeAg seroconversion	Proportion of patients achieving HBeAg seroconversion at weeks 48, 96, 144	Week 48, 96 and 144
Primary	Evaluation the percentage of Participants with Hepatitis B Virus (HBV) DNA < 20 IU/mL	The primary efficacy endpoint was the proportion of patients with HBV DNA < 20 IU/mL at week 48 in all patients who are randomly assigned and received HS-10234 25 mg or TDF 300 mg. The safety and tolerance were also observed in two treatment groups.	Week 48
Secondary	Evaluation the percent Change from Baseline in Hip BMD	Percent Change from Baseline in Hip Bone Mineral Density (BMD) at Week 48	Week 48
Secondary	Evaluation the percent Change from Baseline in Spine BMD	Percent Change from Baseline in Spine BMD at Week 48	Week 48
Secondary	Evaluation the change from Baseline in Serum Creatinine	Change from Baseline in Serum Creatinine at Week 48	Week 48